文献速递艾滋病与性传播感染

利匹韦林或达芦那韦方案抗逆转录病毒治疗48周内左炔诺孕酮与依托孕烯避孕植入剂的药代动力学

Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

两项平行、三组、非随机药代动力学研究评估依托孕烯或左炔诺孕酮植入剂在利匹韦林或达芦那韦方案抗逆转录病毒治疗女性中的药代动力学。第24周利匹韦林组孕激素浓度与无HIV对照组相似,达芦那韦组较高,结果持续至第48周。两种植入剂均可作为上述抗逆转录病毒治疗方案下的避孕选择。

要点

  • 第24周利匹韦林组依托孕烯GMR 1.18(0.99-1.37)、左炔诺孕酮GMR 1.16(0.97-1.33),与对照组相似。
  • 第24周达芦那韦组依托孕烯GMR 2.56(1.69-3.28)、左炔诺孕酮GMR 1.89(1.38-2.29),高于对照组。
  • 两种孕激素释放植入剂均可作为利匹韦林或达芦那韦/利托那韦方案抗逆转录病毒治疗下的避孕选择。

核心结论

  • 依托孕烯和左炔诺孕酮浓度未受利匹韦林方案抗逆转录病毒治疗影响。
  • 含利托那韦增效达芦那韦的抗逆转录病毒治疗组孕激素浓度较高,但未观察到植入剂相关严重不良事件。
  • 两种孕激素释放植入剂均可作为利匹韦林或达芦那韦/利托那韦方案抗逆转录病毒治疗下的避孕选择。

研究设计与样本

  • 两项独立、平行、三组、非随机药代动力学研究,分别评估依托孕烯或左炔诺孕酮。
  • 研究对象为接受利匹韦林或达芦那韦方案抗逆转录病毒治疗的女性,对照为无HIV女性。
  • 抗逆转录病毒治疗组在植入前分别接受利匹韦林方案6周导入期或达芦那韦方案2周导入期。
  • 于第0天及植入后第1、4、12、24、36和48周采集血浆。
  • 采用几何均值比(GMR)和90%CI比较抗逆转录病毒治疗组与对照组的血浆孕激素浓度。

主要发现

  • 主要终点第24周,利匹韦林组与对照组孕激素浓度相似:依托孕烯GMR 1.18(0.99-1.37);左炔诺孕酮GMR 1.16(0.97-1.33)。
  • 第24周,达芦那韦组孕激素暴露高于对照组:依托孕烯GMR 2.56(1.69-3.28);左炔诺孕酮GMR 1.89(1.38-2.29)。
  • 结果持续至第48周保持一致。
  • 未观察到依托孕烯相关不良事件差异,但两个抗逆转录病毒治疗组使用左炔诺孕酮时月经异常均多于对照组。

临床怎么用

  • 两种孕激素释放植入剂均可作为利匹韦林或达芦那韦/利托那韦方案抗逆转录病毒治疗下的避孕选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pharmacokinetic data are lacking for progestin-releasing subdermal contraceptive implants when used with either rilpivirine- or darunavir/ritonavir-based ART. OBJECTIVES: To characterize the pharmacokinetics of etonogestrel or levonorgestrel implants when administered with these ART regimens over 48 weeks. PATIENTS AND METHODS: Two separate, parallel, three-group, non-randomized, pharmacokinetic studies evaluated either etonogestrel or levonorgestrel in women receiving rilpivirine- or darunavir-based ART compared with women without HIV (control group). Participants on ART were switched to rilpivirine-based ART with a run-in period of 6 weeks or darunavir-based ART with a run-in of 2 weeks prior to implant insertion. Plasma was collected on Day 0, and 1, 4, 12, 24, 36 and 48 weeks post-insertion. Plasma progestin concentrations were compared between ART and control groups by geometric mean ratio (GMR) and 90% CI. RESULTS: At the primary endpoint of Week 24, progestin concentrations were similar between the rilpivirine and control groups [etonogestrel: 1.18 (0.99-1.37); levonorgestrel: 1.16 (0.97-1.33)]. At Week 24, progestin exposure was higher in the darunavir groups compared with the control group [etonogestrel: 2.56 (1.69-3.28); levonorgestrel: 1.89 (1.38-2.29)]. Results remained consistent through to Week 48. No differences in etonogestrel-related adverse events were observed, but both ART groups experienced more menstrual abnormalities versus the control group with levonorgestrel. CONCLUSIONS: Etonogestrel and levonorgestrel concentrations were not altered by rilpivirine-based ART. Although progestin concentrations were higher in the ART groups containing ritonavir-boosted darunavir, no implant-related serious adverse events were observed. Both progestin-releasing implants are an appropriate contraceptive option with either rilpivirine- or darunavir/ritonavir-based ART.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Nakalema S, Chappell CA, Pham M, et al. Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy. J Antimicrob Chemother. 2022. PMID: 36059130. doi:10.1093/jac/dkac296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。